Cargando…

Efficacy and Tolerability of RAL, MVC and ETV used in combination in the treatment of highly treatment experienced HIV infected patients

Detalles Bibliográficos
Autores principales:	Khanlou, Homayoon, Sayana, Shilpa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316047/ http://dx.doi.org/10.1186/1742-4690-7-S1-P48

Ejemplares similares

Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
por: Furtado, JJD, et al.
Publicado: (2010)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
por: Bhatti, L, et al.
Publicado: (2010)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
por: Schneider, L, et al.
Publicado: (2010)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
por: Despiegel, Nicolas, et al.
Publicado: (2012)

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
por: Lazzarin, A, et al.
Publicado: (2010)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Evaluation of adipose tissue changes with bioimpedance and dual-energy X-ray absorptiometry in treatment of multi-experienced HIV-infected patients
por: Mihăilescu, Raluca, et al.
Publicado: (2014)

Difficulties in controlling HIV and TB infections in multi-experienced patients
por: Benea, Șerban, et al.
Publicado: (2014)

ASP.NET MVC in action: with MvcContrib, NHibernate, and more
por: Palermo, Jeffrey, et al.
Publicado: (2010)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
por: Ghosn, J, et al.
Publicado: (2010)

Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy
por: Gaytán-Martínez, JE, et al.
Publicado: (2010)

Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)
por: Pérez, L, et al.
Publicado: (2010)

Life after the MVC
por: Tzovanakis, Harris
Publicado: (2017)

Pro PHP MVC
por: Pitt, Chris
Publicado: (2012)

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
por: Doroana, M, et al.
Publicado: (2010)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Effect of range of spread of CD4 count and RNA level on the efficacy of HIV treatments
por: Towfic, George, et al.
Publicado: (2010)

Emergence of HIV-1 drug resistance in antiretroviral therapy experienced perinatally infected children in South India
por: Neogi, Ujjwal, et al.
Publicado: (2012)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
por: Aurora, SK, et al.
Publicado: (2013)

Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
por: Casado, JL, et al.
Publicado: (2010)

Endoscopic third ventriculostomy (ETV) for treatment of adult hydrocephalus: long-term followup with 163 patients
por: Isaacs, Albert, et al.
Publicado: (2015)

CTA at RAL
por: Patargias, George
Publicado: (2022)

Learn ASP.NET MVC
por: Weil, Arnaud
Publicado: (2015)

Professional ASPNET MVC 3
por: Galloway, Jon, et al.
Publicado: (2011)

Differential involvement of RalA and RalB in colorectal cancer
por: Martin, Timothy D., et al.
Publicado: (2012)

Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study)
por: Rodriguez, JM, et al.
Publicado: (2010)

Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned
por: Bayingana, R, et al.
Publicado: (2012)

Learning ASP.NET Core MVC programming: learn the fundamentals of ASP.NET MVC and build real-world web applications using ASP.NET Core MVC
por: Ragupathi, Mugilan T S
Publicado: (2016)

Access to HIV treatment and care in Armenia
por: Grigoryan, S, et al.
Publicado: (2012)

RalA and RalBP1 regulate mitochondrial fission at mitosis
por: Kashatus, David F., et al.
Publicado: (2011)

The Guinean traditional medicine in the treatment of HIV/AIDS
por: Baldé, AM, et al.
Publicado: (2006)

Pro ASPNET MVC 2 Framework
por: Freeman, A, et al.
Publicado: (2010)

Professional ASP.NET MVC 2
por: Galloway, Jon, et al.
Publicado: (2010)

ASP.NET MVC 2 in action
por: Palermo, Jeffrey
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5b63qprv0doe81n1ltcnbl9em1